<DOC>
	<DOCNO>NCT01023386</DOCNO>
	<brief_summary>This study investigate pharmacokinetics YM155 , identify metabolic profile YM155 evaluate safety tolerability YM155 3-hour infusion patient advance cancer</brief_summary>
	<brief_title>A Clinical Pharmacological Study YM155 After Intravenous Infusion Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Patients histologically cytologically confirm locally advanced metastatic solid tumor nonHodgkin 's lymphomas YM155 potential , base preclinical and/or clinical data , show efficacy , namely : castrate resistant prostate cancer nonsmall cell lung cancer metastatic melanoma muscle invasive bladder cancer follicular lymphoma diffuse large Bcell lymphoma Life expectancy ≥ 3 month ; Performance status ( PS ) ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) scale baseline Radiotherapy , major surgery , hormonal therapy , chemotherapy within 4 week prior first dose study medication 6 week case mitomycinC nitrosourea Previous therapy YM155 Patients renal , hepatic colorectal cancer Inadequate bone marrow , renal and/or hepatic function History treat malignancy within 5 year except treat basal squamous cell carcinoma skin Participation clinical study within 4 week prior start first dose study medication Known brain leptomeningeal metastasis Active uncontrolled systemic infection baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>YM155</keyword>
	<keyword>Mass-balance</keyword>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>